News
Sonnet BioTherapeutics Announces A Publication Demonstrating Safety And Tolerability Of SON-1010 In Healthy Volunteers
29 Feb 24
Biotech, News, General
Chardan Capital Maintains Buy on Sonnet BioTherapeutics, Lowers Price Target to $30
15 Feb 24
News, Price Target, Analyst Ratings
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
14 Feb 24
Movers
Sonnet BioTherapeutics Q1 EPS $(0.31) May Not Be Comparable To $(0.90) Estimate, Sales $18.63K Beat $18.00K Estimate
14 Feb 24
Earnings, News
12 Health Care Stocks Moving In Tuesday's After-Market Session
13 Feb 24
Movers
Press releases
Sonnet BioTherapeutics to Present Preclinical Data on SON-080 for Chemotherapy-Induced Peripheral Neuropathy (CIPN) at the AACR 2024 Annual Meeting
19 Mar 24
News, Press Releases
Sonnet BioTherapeutics Announces Early Safety Data from the Company's Phase 1b/2a Clinical Trial of SON-080 in Chemotherapy-Induced Peripheral Neuropathy (CIPN) Met the Study's Initial Pre-Specified Objective
11 Mar 24
News, Press Releases
Sonnet BioTherapeutics Provides Fiscal Year 2024 First Quarter Business and Earnings Update
14 Feb 24
Earnings, Press Releases